U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H16ClNO2S.ClH
Molecular Weight 358.283
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOPIDOGREL HYDROCHLORIDE

SMILES

Cl.COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=CC=CC=C3Cl

InChI

InChIKey=XIHVAFJSGWDBGA-RSAXXLAASA-N
InChI=1S/C16H16ClNO2S.ClH/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;/h2-5,7,9,15H,6,8,10H2,1H3;1H/t15-;/m0./s1

HIDE SMILES / InChI
Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. Plavix (clopidogrel bisulfate) is an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADPmediated activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADPmediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

1997
Primary
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

1997
Primary
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

1997
Preventing
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1500 pg/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
15800 pg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2520 pg/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
4600 pg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.521 ng/mL
75 mg single, oral
dose: 75 mg
route of administration: oral
experiment type: single
co-administered:
CLOPIDOGREL plasma
Homo sapiens
population: healthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3130 pg × h/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
50600 pg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7440 pg × h/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
9890 pg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.767 ng*h/mL
75 mg single, oral
dose: 75 mg
route of administration: oral
experiment type: single
co-administered:
CLOPIDOGREL plasma
Homo sapiens
population: healthy
age:
sex:
food status:
1.09 ng*h/mL
75 mg single, oral
dose: 75 mg
route of administration: oral
experiment type: single
co-administered:
CLOPIDOGREL plasma
Homo sapiens
population: healthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.5 h
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.4 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7.4 h
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7.9 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
unknown, unknown
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral (starting)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 20-45 years
n = 27
Health Status: healthy
Age Group: 20-45 years
Sex: M
Population Size: 27
Sources:
Other AEs: Uric acid abnormal...
Other AEs:
Uric acid abnormal (5 patients)
Sources:
1650 mg single, oral
Overdose
Dose: 1650 mg
Route: oral
Route: single
Dose: 1650 mg
Co-administed with::
phenytoin sodium(1400 mg; single)
simvastatin(120 mg; single)
Sources:
unknown, 49 years
n = 1
Health Status: unknown
Age Group: 49 years
Sex: M
Population Size: 1
Sources:
600 mg 1 times / day multiple, oral (starting)
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Transaminases increased, Fever...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (1 patient)
Fever (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Uric acid abnormal 5 patients
600 mg 1 times / day multiple, oral (starting)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 20-45 years
n = 27
Health Status: healthy
Age Group: 20-45 years
Sex: M
Population Size: 27
Sources:
Fever 1 patient
Disc. AE
600 mg 1 times / day multiple, oral (starting)
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: F
Population Size: 1
Sources:
Transaminases increased 1 patient
Disc. AE
600 mg 1 times / day multiple, oral (starting)
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: F
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
Drug-induced thrombotic microangiopathy: incidence, prevention and management.
2001
Atherothrombosis: a major health burden.
2001
Novel platelet inhibitors.
2001
The use of antiplatelet agents in acute cardiac care.
2001 Apr
Aspirin in patients with coronary artery disease: is it simply irresistible?
2001 Apr
CURE--clopidogrel's major advance.
2001 Apr
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
2001 Apr
[Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
2001 Apr
Clinical and angiographical follow-up after implantation of a 6--12 microCi radioactive stent in patients with coronary artery disease.
2001 Apr
Bench to bedside: the development of rapamycin and its application to stent restenosis.
2001 Aug 21
Severe hypersensitivity associated with clopidogrel.
2001 Aug 21
Newer antiplatelet therapies in stroke prevention.
2001 Feb
Antiplatelet therapy in the elderly. Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists.
2001 Feb
Thrombolysis and antithrombotic therapy for coronary artery disease.
2001 Feb
Antithrombotic and thrombolytic therapy for ischemic stroke.
2001 Feb
Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement.
2001 Feb 1
Fatal aplastic anaemia associated with clopidogrel.
2001 Feb 10
Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting.
2001 Feb 15
[Clopidogrel? Known or known?].
2001 Jan
Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report.
2001 Jan
[2 platelet inhibitors administered at the same time. Improved prognosis in myocardial infarct?]].
2001 Jan 11
Identification of the platelet ADP receptor targeted by antithrombotic drugs.
2001 Jan 11
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.
2001 Jan 23
Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting.
2001 Jan 25
Febrile pancytopenia associated with clopidogrel.
2001 Jan 8
Clopidogrel (Plavix): hematological reactions.
2001 Jan 9
The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease.
2001 Jul
Extensive thrombus prior to elective percutaneous coronary intervention.
2001 Jul
Diffuse alveolar hemorrhage after clopidogrel use.
2001 Jul
The P2Y12 receptor as a therapeutic target in cardiovascular disease.
2001 Jun
[Toxic skin reaction to clopidogrel].
2001 Jun
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].
2001 Mar
[Acute coronary syndromes: an update. II. Coronary revascularization and risk stratification].
2001 Mar
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
2001 Mar
[Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery].
2001 May
The inhibition of oxygen radical release from human neutrophils by resting platelets is reversed by administration of acetylsalicylic acid or clopidogrel.
2001 May
New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
2001 May
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings.
2001 May 1
Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS).
2001 May 15
P2y(12), a new platelet ADP receptor, target of clopidogrel.
2001 May 4
Clopidogrel and aplastic anaemia.
2001 May 5
Prospective controlled study of carotid endarterectomy with hemashield patch: is it thrombogenic?
2001 May-Jun
Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy.
2001 Nov 1
[Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial].
2001 Oct
Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting.
2001 Oct
Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
2001 Sep
Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting.
2001 Sep
Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro.
2001 Sep
Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.
2001 Sep
Complications of oral antiplatelet medications.
2001 Sep
Patents

Sample Use Guides

Recent MI, Recent Stroke, or Established Peripheral Arterial Disease The recommended daily dose of is 75 mg once daily.
Route of Administration: Oral
Incubation of human washed platelets with clopidogrel resulted in a time- (maximum effects after 30 min) and concentration-dependent (IC50 1.9+/-0.3 uM) inhibition of ADP (6 uM)-induced platelet aggregation. Clopidogrel (30 uM) did not inhibit collagen (2.5 ug ml(-1))-, U46619 (1 uM)- or thrombin (0.1 u ml(-1))-induced platelet aggregation.
Name Type Language
CLOPIDOGREL HYDROCHLORIDE
EMA EPAR   WHO-DD  
Common Name English
CLOPIDOGREL TEVA GENERICS B.V.
Brand Name English
CLOPIDOGREL HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
CLOPIDOGREL-TAD
Brand Name English
CLOPIDOGREL QUALIMED
Brand Name English
CLOPIDOGREL HYDROCHLORIDE [EMA EPAR]
Common Name English
CLOPIDOGREL-DURA
Brand Name English
Clopidogrel hydrochloride [WHO-DD]
Common Name English
CLOPIDOGREL TEVA PHARMA
Brand Name English
CLOPIDOGREL-HCS
Brand Name English
CLOPIDOGREL-KRKA
Brand Name English
THIENO(3,2-C)PYRIDINE-5(4H)-ACETIC ACID, .ALPHA.-(2-CHLOROPHENYL)-6,7-DIHYDRO-, METHYL ESTER, HYDROCHLORIDE, (S)-
Common Name English
CLOPIDOGREL MYLAN
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS CLOPIDOGREL KRKA (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL-TAD (AUTHORIZED: STROKE)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL-HCS (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL KRKA D.D. (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL KRKA (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA PHARMA (AUTHORIZED: STROKE)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL TAD (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL-HCS (AUTHORIZED: STROKE)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL DURA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL QUALIMED (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL QUALIMED (WITHDRAWN: STROKE)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL-DURA (WITHDRAWN: STROKE)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL MYLAN (AUTHORIZED: STROKE)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA PHARMA (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: STROKE)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL KRKA D.D. (AUTHORIZED: STROKE)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL-KRKA (AUTHORIZED: STROKE)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL KRKA D.D. (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL QUALIMED (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL DURA (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
NCI_THESAURUS C80483
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL TEVA PHARMA (AUTHORIZED: AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL-HCS (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL MYLAN (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL TAD (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL HCS (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
EMA ASSESSMENT REPORTS CLOPIDOGREL MYLAN (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
Code System Code Type Description
DRUG BANK
DBSALT002594
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
PRIMARY
SMS_ID
100000115888
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
PRIMARY
CAS
120202-65-5
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
PRIMARY
PUBCHEM
9798860
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
PRIMARY
FDA UNII
426O7XWS6Y
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
PRIMARY
NCI_THESAURUS
C96893
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
PRIMARY
EVMPD
SUB30779
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
PRIMARY
EPA CompTox
DTXSID40152734
Created by admin on Fri Dec 15 17:57:17 GMT 2023 , Edited by admin on Fri Dec 15 17:57:17 GMT 2023
PRIMARY